<DOC>
	<DOCNO>NCT00867711</DOCNO>
	<brief_summary>The aim present study investigate molecular predictor pemetrexed carboplatin response tumor sample series MPM patient extract DNA genotyping TSER polymorphism .</brief_summary>
	<brief_title>Molecular Predictors Pemetrexed Carboplatin Response Malignant Pleural Mesothelioma ( MPM ) Patients</brief_title>
	<detailed_description>Malignant pleural mesothelioma ( MPM ) aggressive tumor usually poor prognosis . The combination cisplatin pemetrexed recently become standard care first-line treatment MPM . For patient unfit receive cisplatin-based chemotherapy , pemetrexed alone [ 7 ] combine carboplatin [ 8 ] propose alternative treatment choice . The identification molecular predictor effective therapy important maximizing therapeutic efficacy minimize useless treatment cancer patient .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>MPM diagnosis Availability tumor tissue perform analysis Exclusion Criteria : Other primary diagnosis No archival tissue available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>